Today, AbbVie announced that the F.D.A. approved the inclusion of moderate to severe fingernail psoriasis data in the HUMIRA® (adalimumab) prescribing information for patients with moderate to severe chronic plaque psoriasis. Fingernail psoriasis affects half of all psoriasis patients and HUMIRA is now the first-and-only biologic treatment with data on fingernail psoriasis in its U.S. prescribing information.